Letter: cytokeratin‐18 as a biomarker of hepatocellular carcinoma regression after transarterial chemoembolization. Authors’ reply

H. Bantel,F. Wandrer,B. Bock,M. Kirstein,K. Schulze-Osthoff
DOI: https://doi.org/10.1111/apt.13826
2017-01-01
Abstract:their responders and nonresponders, preventing them from performing uniand multivariate analyses that would provide a more rigorous assessment of the ability of CK-18, alone or in combination with other well-established prognostic factors, to serve as an index or even predictor of HCC regression after TACE. Another factor limiting the conclusions of Bock et al. is heterogeneity in their patients’ treatment histories. Of the 48 patients in their study, 14 (29%) underwent hepatic resection before TACE. Resection has been shown to affect CK-18 levels. This makes treatment history a potential confounder in their analysis, for which they could not adjust because of the small sample and the lack of unior multivariate analysis. While we commend Bock et al. for providing some of the first evidence suggesting the potential of cell death markers for assessing patient response to locoregional HCC therapies, their conclusions remain highly preliminary and must be verified in much larger studies that take into account the complex array of patientand HCC-related factors that can determine response to treatment and overall prognosis.
What problem does this paper attempt to address?